{"id":38572,"date":"2026-05-26T09:45:00","date_gmt":"2026-05-26T13:45:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=38572"},"modified":"2026-04-28T08:49:05","modified_gmt":"2026-04-28T12:49:05","slug":"mark-cubans-cost-plus-drugs-vs-big-pharma-the-strategic-war-you-need-to-be-modeling-right-now","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/mark-cubans-cost-plus-drugs-vs-big-pharma-the-strategic-war-you-need-to-be-modeling-right-now\/","title":{"rendered":"Mark Cuban’s Cost Plus Drugs vs. Big Pharma: The Strategic War You Need to Be Modeling Right Now"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Mark Cuban did not build a pharmacy. He built a mirror and pointed it at an industry that had never been forced to look at itself.<\/p>\n\n\n\n

When the Mark Cuban Cost Plus Drug Company (MCCPDC) launched in January 2022 with 111 generic medications and a pricing model so stripped-down it could be explained on a napkin \u2014 acquisition cost plus 15%, a $3 pharmacy fee, and a $5 shipping charge \u2014 the initial reflex from the pharmaceutical establishment was contempt. The company didn’t have a lobbying arm. It didn’t have a PBM contract. It didn’t have relationships with the formulary committees that determine which drugs actually reach patients in the United States. What it had was a celebrity co-founder, a transparent pricing website, and a radiologist-turned-CEO named Dr. Alex Oshmyansky with a vision to manufacture drugs that nobody else wanted to bother with.<\/p>\n\n\n\n

Four years later, Cost Plus Drugs has over 2,500 medications on its platform, more than 2 million members, a robotics-equipped manufacturing facility in Dallas, a partnership with Humana’s CenterWell Pharmacy, and a collaboration with TrumpRx \u2014 the federal government’s own direct-to-consumer drug-purchasing website. Meanwhile, Eli Lilly launched LillyDirect, Novo Nordisk stood up NovoCare Pharmacy, AstraZeneca built its own DTC portal, Bristol Myers Squibb slashed Eliquis prices by up to 80% for cash patients, and 17 of the largest pharmaceutical manufacturers on earth signed most-favored-nation pricing deals with the White House.<\/p>\n\n\n\n

None of those things were coming if Cost Plus Drugs hadn’t shown the public what drug prices actually look like when no one is skimming.<\/p>\n\n\n\n

This is the story of how one transparent pricing model has forced a structural rethink across an industry worth more than $500 billion per year in the United States alone \u2014 and what every executive, investor, and competitive intelligence professional needs to understand about where the channel war goes from here.<\/p>\n\n\n\n

\n\n\n\n

Part I: The Machine Cost Plus Walked Into<\/strong><\/h2>\n\n\n\n

How the PBM System Became the Actual Drug Pricing Mechanism<\/strong><\/h3>\n\n\n\n

To understand why Cost Plus Drugs matters, you need to understand the system it disrupted. Most discussions of drug pricing focus on manufacturers. That is the wrong place to look.<\/p>\n\n\n\n

The real price-setting mechanism in the U.S. pharmaceutical market runs through pharmacy benefit managers. The six largest PBMs \u2014 CVS Caremark, Express Scripts, OptumRx, Humana Pharmacy Solutions, MedImpact, and Prime Therapeutics \u2014 now collectively manage approximately 94% of all prescriptions filled in the United States, according to a July 2024 FTC interim staff report [1]. The top three alone, known as the “Big 3,” process nearly 80% of the approximately 6.6 billion prescriptions dispensed annually, serving roughly 270 million Americans [1]. <blockquote> “The six largest PBMs now manage 94 percent of prescription drug claims.” \u2014 FTC Interim Staff Report on Pharmacy Benefit Managers, July 2024 [1] <\/blockquote><\/p>\n\n\n\n

This concentration is not a recent development. In 2004, the top three PBMs managed 52% of prescription drug claims. The 42-percentage-point gain in share over two decades came through horizontal consolidation \u2014 acquisitions within the PBM space \u2014 and vertical integration, where PBMs merged with or were acquired by health insurers and pharmacy chains. CVS owns both CVS Caremark and CVS Pharmacy. UnitedHealth Group owns OptumRx. Cigna owns Express Scripts. Each entity now manages the formulary, owns a piece of the insurance plan, and dispenses the drugs through an affiliated specialty pharmacy. The conflict of interest is structural, not incidental.<\/p>\n\n\n\n

The FTC documented a specific consequence of this arrangement: pharmacies affiliated with the Big 3 PBMs received 68% of dispensing revenue generated by specialty drugs in 2023, up from 54% in 2016 [1]. That shift in revenue share \u2014 14 percentage points over seven years \u2014 came largely at the expense of independent pharmacies that had no leverage in contract negotiations and no recourse when PBMs imposed direct and indirect remuneration (DIR) fees, retroactive clawbacks that could arrive months after a prescription was filled.<\/p>\n\n\n\n

The rebate system compounds this. Brand drug manufacturers pay rebates to PBMs in exchange for favorable formulary placement. This creates a counterintuitive incentive: a PBM maximizes rebate revenue by favoring high-list-price drugs, since rebates are typically calculated as a percentage of list price. A biosimilar with a low list price generates a smaller rebate even if its net cost to the health plan is also lower. The economic logic pushes PBMs toward expensive brands and away from generics or biosimilars that might actually cost payers less.<\/p>\n\n\n\n

Cuban has been specific about the consequences. Patients have told Cost Plus Drugs they were charged 100 times more for specialty drugs like Imatinib or Droxidopa than what they or their employers would pay through Cost Plus Drugs. The FTC’s second interim report, released in January 2025, found that the Big 3 PBMs marked up certain specialty generic cancer drugs \u2014 including imatinib, the generic version of Gleevec \u2014 by thousands of percent at their affiliated specialty pharmacies [2]. The same report found that the Big 3 collectively generated about $1.4 billion of income from spread pricing on assessed specialty generic drugs, and that plan sponsors paid $4.8 billion for specialty generic drugs while patient cost sharing ballooned to $297 million.<\/p>\n\n\n\n

This is the system Cost Plus Drugs walked into. The pricing on Cuban’s website \u2014 $34.70 for a 30-count supply of 400mg generic imatinib, against a retail price of $9,657.30 \u2014 is not a marketing stunt [3]. It is what the drug actually costs when no one is skimming.<\/p>\n\n\n\n

Why Generics Are Not the Whole Story<\/strong><\/h3>\n\n\n\n

Critics of Cost Plus Drugs have a legitimate point when they note that the company operates almost entirely in the generic drug market, and that generics are already cheap by global standards. Ezekiel J. Emanuel and John Connolly wrote in STAT News in July 2024 that of the 211 generic drugs offered by MCCPDC that begin with the letter ‘A’, at least 141 (67%) were priced higher by Cuban’s company than by one or more pharmacies on GoodRx according to a 2023 analysis, and that a June 2024 analysis suggests that people would be better off purchasing through MCCPDC, as opposed to using their own health insurance, in less than 12% of cases for generic drugs.<\/p>\n\n\n\n

The Emanuel critique is worth taking seriously. It identifies the ceiling on Cost Plus Drugs’ direct consumer savings impact. Generics are already cheap. The 80-90% price reduction from brand to generic happens at patent expiration, before Cost Plus Drugs enters the picture. What Cost Plus is doing at the consumer level is narrowing the spread between generic acquisition cost and what patients are actually charged \u2014 a gap that exists because of PBM markup, specialty designation, and the DIR fee system.<\/p>\n\n\n\n

But there are two other impacts that the price-comparison analysis misses. The first is what a PharmacoEconomics study found in August 2024: total estimated Medicare Part D savings were $8.6 billion using 90-day CostPlusDrugs.com pricing, with surgical drugs accounting for over $900 million. Nearly 80% of the examined drugs were more price effective through CostPlusDrugs.com using 90-day supply. The Medicare savings case is considerably stronger than the retail comparison case, because Medicare drug pricing is not set against acquisition cost but against a negotiated benchmark that PBMs and plan sponsors control.<\/p>\n\n\n\n

The second impact is harder to quantify but more important strategically: Cost Plus Drugs published the underlying cost structure of the pharmaceutical supply chain in a way that no PBM, wholesaler, or retailer had ever done. That information changed the negotiating leverage of every employer, health plan, and hospital system in the country.<\/p>\n\n\n\n

\n\n\n\n

Part II: What Cost Plus Actually Built<\/strong><\/h2>\n\n\n\n

The Pricing Model and Its Mechanics<\/strong><\/h3>\n\n\n\n

The business model of Cost Plus Drugs has three components: a consumer-facing pharmacy that sells generics direct to patients at a transparent markup; a B2B marketplace called Cost Plus Marketplace where hospitals and clinics buy drugs at the same pass-through pricing; and a manufacturing operation in Dallas that produces injectable drugs prone to shortage.<\/p>\n\n\n\n

Cost Plus Drugs employs a simple pricing model in which medicines are sold for a fully disclosed cost plus a 15% markup, a $5 pharmacy service fee, and a $5 shipping fee. The fee structure is public on the website for every drug. There are no formulary restrictions, no rebate negotiations, no specialty tier. The site that started with 111 generic drugs now offers more than 2,500.<\/p>\n\n\n\n

The company grew to over 2 million members with zero dollars spent on traditional marketing, relying on word of mouth and Cuban’s public profile. Cuban’s own explanation of why this worked: “This industry is the easiest industry I’ve ever disrupted. And all it took was transparency and just telling the truth.”<\/p>\n\n\n\n

The platform does have structural limitations. Because it bypasses insurance and PBMs, it functions as a cash-pay pharmacy. DTC platforms that cut out PBMs become de facto cash-only pharmacies that cannot accept insurance plans, limiting who can benefit from the savings. A patient on a plan managed by CVS Caremark whose employer’s formulary is built around PBM rebates cannot simply switch to Cost Plus Drugs and get reimbursed. They pay out of pocket. That constraint matters for the 160-plus million Americans who get insurance through their employers \u2014 which is precisely why Cuban has pushed so hard into the employer market.<\/p>\n\n\n\n

SwiftyRx and the B2B Pivot<\/strong><\/h3>\n\n\n\n

The consumer-facing pharmacy is the visible face of Cost Plus Drugs. The strategic core is increasingly the employer channel. Cuban’s recognition that the consumer DTC model hits a ceiling is embedded in the company’s recent moves.<\/p>\n\n\n\n

Cost Plus Drugs built SwiftyRx, a software platform for pharmacy order management, as the technology layer that can plug into existing pharmacy distribution infrastructure. The partnership with CenterWell Pharmacy, announced in April 2026, sees CenterWell Pharmacy adopt Cost Plus Drugs’ SwiftyRx for its medication order intake, automating benefit checks, streamlining patient onboarding, and reducing cost-to-fill. SwiftyRx becomes the operating system; CenterWell becomes the distribution rail.<\/p>\n\n\n\n

This is the structure that makes Cost Plus Drugs interesting to health systems, self-insured employers, and payers who want to bypass PBM markup on generics without building their own pharmacy infrastructure. Cuban has been explicit about the strategic logic: “160-plus million people are getting their insurance through private or public employers. Those employers don’t like the bigger PBMs any more than anybody else does, and they’re getting ripped off by them.”<\/p>\n\n\n\n

CenterWell Pharmacy recorded nearly $13 billion in revenue in 2025, up from $11.6 billion in 2024. By combining SwiftyRx’s technology, Cost Plus Drugs’ pass-through pricing, and CenterWell Pharmacy’s distribution capabilities, the organizations intend to partner on a new employer-based program design.<\/p>\n\n\n\n

This employer-channel pivot is where Cost Plus Drugs potentially moves from a niche consumer play to a genuine structural alternative to the traditional PBM model for generic drug distribution. If a large self-insured employer with 50,000 employees can route their generic prescriptions through SwiftyRx and CenterWell at Cost Plus pricing, the savings relative to what a Big 3 PBM would charge are not incremental. They are categorical.<\/p>\n\n\n\n

The Manufacturing Play and Drug Shortages<\/strong><\/h3>\n\n\n\n

The least-discussed but most strategically interesting piece of Cost Plus Drugs is its manufacturing operation. The $11 million drug manufacturing plant in Dallas’ Deep Ellum neighborhood, which originally planned to start operating in late 2022, focuses on producing injectable drugs that often fall into shortages. In early 2024, MCCPDC began production of epinephrine and norepinephrine.<\/p>\n\n\n\n

The manufacturing facility’s design reflects a specific theory of change. The plant’s robotic and AI technology allows Cost Plus Drugs “to pivot from making one drug type to another very rapidly \u2014 in principle, within four hours,” according to CEO Alex Oshmyansky. That agility addresses a structural failure in generic injectable manufacturing: drugs go into shortage because manufacturers with thin margins on high-volume, low-price products have no incentive to invest in excess capacity. When one of the two or three producers of a critical injectable drug experiences a quality failure or supply disruption, there is no buffer.<\/p>\n\n\n\n

The FDA currently reports shortages of more than 100 medications. MCCPDC has the potential to infuse serious capital into correcting the market failure of generic drug shortages. The manufacturing operation started with epinephrine \u2014 which has been in unsteady supply since 2012 \u2014 and norepinephrine, with pediatric oncology drugs on the immediate roadmap.<\/p>\n\n\n\n

Community Health Systems, one of the nation’s largest healthcare companies with 71 affiliated hospitals, became Cost Plus Drugs’ first health system partner, purchasing epinephrine and norepinephrine at a transparent cost-plus price. This is a different business than the consumer pharmacy. It positions Cost Plus as a supplier to hospital pharmacy departments that are otherwise entirely dependent on the Big 3 pharmaceutical distributors \u2014 McKesson, AmerisourceBergen (now Cencora), and Cardinal Health.<\/p>\n\n\n\n

The manufacturing play also addresses a geopolitical risk that has nothing to do with PBMs. As of 2025, China produces approximately 40-45% of the Key Starting Materials and Active Pharmaceutical Ingredients for the global generic market. Domestic manufacturing of critical injectables reduces exposure to supply chain disruptions that could result from trade policy changes, export controls, or quality failures at Chinese API manufacturers. That argument resonates in Washington regardless of which party is in power.<\/p>\n\n\n\n

\n\n\n\n

Part III: The Patent Landscape Cost Plus Drugs Exploits<\/strong><\/h2>\n\n\n\n

The Generic Drug Entry Machine<\/strong><\/h3>\n\n\n\n

Cost Plus Drugs operates in a space that exists because of patent expiration. Every drug on its formulary was once a branded product protected by one or more patents. When those patents expired, generic manufacturers filed Abbreviated New Drug Applications (ANDAs) with the FDA, and competition drove prices down. Cost Plus then sources the generic API and finished product at or near acquisition cost and passes that price directly to patients.<\/p>\n\n\n\n

Understanding how patent expiration translates into generic availability is essential to modeling which drugs Cost Plus can add to its formulary and when. The timeline from patent expiration to meaningful generic competition is not instantaneous. It involves the Paragraph IV challenge process under the Hatch-Waxman Act, where generic manufacturers can file ANDAs before patents expire by certifying that the patents are invalid or will not be infringed. A successful Paragraph IV filer receives 180 days of marketing exclusivity \u2014 a period during which no other generic can enter the market. That 180-day window can be worth hundreds of millions of dollars for high-revenue drugs, which is why generic companies treat patent intelligence as a competitive weapon.<\/p>\n\n\n\n

DrugPatentWatch is the standard platform for pharmaceutical IP analysts tracking this lifecycle. It maps which patents cover which drugs, when they expire, what ANDA filings have been made, and which Paragraph IV certifications have triggered litigation. For Cost Plus Drugs’ formulary expansion strategy, this kind of patent expiration intelligence determines which molecules will be available for generic sourcing \u2014 and at what price \u2014 in any given planning window.<\/p>\n\n\n\n

Between 2025 and 2030, the industry anticipates that nearly 200 drugs, including approximately 70 blockbuster medications with annual sales exceeding $1 billion each, will lose their market exclusivity. The total revenue at risk during this window is estimated to exceed $300 billion, with some projections reaching as high as $400 billion by 2033 as foundational patents for top-selling therapies like Keytruda, Eliquis, and Opdivo lapse.<\/p>\n\n\n\n

Each one of those drugs is a candidate for the Cost Plus formulary once it goes generic \u2014 assuming PBMs don’t block the channel through formulary design, specialty tier classification, or direct and indirect remuneration structures that make dispensing the generic economically punishing for non-affiliated pharmacies.<\/p>\n\n\n\n

The Patent Cliff and Its Interaction with Cost Plus Pricing<\/strong><\/h3>\n\n\n\n

The scale of the current patent cliff is worth stating directly. An estimated $200-$230 billion in annual branded revenue will lose exclusivity protection between 2025 and 2030, with drugs like Keytruda ($29B+ in 2024 sales), Eliquis ($13B+ for BMS alone), and Opdivo concentrated in a narrow 2026-2028 window.<\/p>\n\n\n\n

A branded drug can lose between 80% and 90% of its revenue within the first year of facing generic competition, with the originator’s sales plummeting as much as 80-90% within the first year of generic entry. The AbbVie\/Humira example is illustrative. Humira peaked at $21.24 billion in sales in 2022. Following its loss of exclusivity, Humira’s sales declined to $14.04 billion in 2023 and further to $8.99 billion in 2024.<\/p>\n\n\n\n

But the Humira trajectory also illustrates why the generic market is more complex than a simple “patent expires, price drops” model. Humira is a biologic, and its biosimilar competitors faced a more gradual erosion curve than small-molecule generics experience. By 2025, biosimilars had captured approximately 20-30% of the Humira volume, far below the 90% seen in small molecules. This indicates that biologic LOE models must account for a 2-3 year ramp to peak erosion, rather than the 6-month crash of small molecules.<\/p>\n\n\n\n

Cost Plus Drugs’ near-term formulary expansion opportunities sit primarily in the small-molecule generic space, where the revenue cliff is steeper and faster. Drugs like Eliquis (apixaban, patents expiring 2026-2028) and Entresto (sacubitril\/valsartan, facing competition as early as 2025) represent molecules with massive patient populations and correspondingly large savings opportunity once generics enter.<\/p>\n\n\n\n

The strategic implication for manufacturers: every blockbuster that loses exclusivity is a drug that Cost Plus Drugs can potentially price at 85-95% below the former brand price. For manufacturers with pipeline depth, this is manageable. For those who have been living off a single franchise, it is the core threat \u2014 and it is coming whether or not Cost Plus Drugs exists.<\/p>\n\n\n\n

Patent Thickets and the Delayed Cliff<\/strong><\/h3>\n\n\n\n

Brand manufacturers have developed sophisticated responses to the generic entry threat that extend exclusivity beyond the primary compound patent. Patent thickets \u2014 clusters of secondary patents covering formulations, manufacturing processes, dosing regimens, and metabolites \u2014 can delay generic entry by years. The Humira patent thicket is the canonical example: AbbVie assembled more than 250 patents on adalimumab, creating a barrier that kept biosimilars out of the U.S. market until 2023 despite earlier entry in Europe.<\/p>\n\n\n\n

DrugPatentWatch’s databases track these thickets in detail, mapping which secondary patents are most likely to be asserted in litigation and which are most vulnerable to challenge. For a generic manufacturer assessing whether to file a Paragraph IV ANDA on a drug with a thick secondary patent cluster, this analysis determines whether the 180-day first-to-file exclusivity opportunity is worth the litigation cost.<\/p>\n\n\n\n

For Cost Plus Drugs, patent thicket strategy by brand manufacturers creates timeline uncertainty on formulary expansion. A drug whose primary compound patent expires in 2027 may not actually have competitive generic pricing until 2030 if secondary patent litigation extends market exclusivity. The operational implication is that Cost Plus needs ongoing patent surveillance \u2014 essentially the same intelligence that generics companies and their investors use \u2014 to plan formulary additions with any precision.<\/p>\n\n\n\n

The Revlimid case represents the sophistication of modern brand strategy: rather than fight all generic challengers to the bitter end, strategic settlements can be used to engineer a predictable, manageable revenue decline rather than an abrupt cliff. Bristol Myers Squibb used volume-capped settlement agreements to control the pace of generic entry, which allowed analysts to model the revenue trajectory with unusual precision.<\/p>\n\n\n\n

That kind of volume-capped settlement affects Cost Plus Drugs’ ability to source generic lenalidomide at competitive prices. If only a handful of generic manufacturers are permitted to sell, and their volumes are capped under settlement terms, the market price for generic Revlimid will not compress to the extent it would under full open competition. Cost Plus’s 15% markup model depends on being able to source at or near true acquisition cost. Restricted generic markets keep acquisition costs elevated.<\/p>\n\n\n\n

\n\n\n\n

Part IV: Big Pharma’s Strategic Responses<\/strong><\/h2>\n\n\n\n

The Direct-to-Consumer Counter-Attack<\/strong><\/h3>\n\n\n\n

The most direct competitive response to Cost Plus Drugs from Big Pharma has been the proliferation of manufacturer-owned direct-to-consumer platforms. This is not coincidental timing. It is a structural response to the same pressure Cost Plus applies \u2014 the demonstration that removing intermediaries from the drug distribution chain produces dramatically lower patient-facing prices.<\/p>\n\n\n\n

In 2024, Eli Lilly launched LillyDirect, Pfizer launched PfizerForAll, and Astellas launched DIGITIVA \u2014 platforms that went beyond marketing to offer integrated ‘digital front doors’ connecting remote diagnosis, telehealth, e-prescribing, fulfilment, and disease management.<\/p>\n\n\n\n

Novo Nordisk followed in 2025 with NovoCare Pharmacy, focused on stabilizing access to its high-demand GLP-1 therapies Wegovy and Ozempic, providing transparent cash-pay rails by publishing flat prices for GLP-1 therapies. NovoCare launched with Wegovy priced at $499 per month for cash-paying patients \u2014 a significant reduction from the $1,349 list price, though still above what TrumpRx would later negotiate.<\/p>\n\n\n\n

Bristol Myers Squibb announced direct-to-patient platforms for Eliquis and Sotyktu, under which eligible cash-pay patients can purchase the drug at a 40% discount and greater than 80% discount versus their respective list prices. AstraZeneca built its own DTC portal through which patients can access several drugs at up to 70% off list prices with home delivery.<\/p>\n\n\n\n

On September 25th, Bristol Myers Squibb announced direct-to-patient platforms for Eliquis and Sotyktu. A day after, on September 26th, AstraZeneca announced a U.S. direct-to-patient online platform for patients to access several of its drugs for a cash price up to 70% off their list prices with home delivery, starting October 1st, 2025.<\/p>\n\n\n\n

These moves have a consistent strategic logic: they allow manufacturers to demonstrate lower prices to patients without formally reducing the list price that serves as the basis for PBM rebate negotiations. If a drug’s list price is $1,000 per month but patients can buy it directly for $350, the PBM’s rebate calculation is still anchored to $1,000. The manufacturer preserves its rebate negotiating leverage while appearing to respond to the pricing transparency pressure Cost Plus created.<\/p>\n\n\n\n

This is a significant difference from Cost Plus Drugs’ model. Cost Plus publishes acquisition cost. The manufacturer DTC platforms publish a discounted consumer price, but the underlying economics of the rebate system remain intact. Whether regulators and payers eventually force manufacturers to reconcile the “real” price with the list price is the central unresolved question in pharmaceutical pricing policy.<\/p>\n\n\n\n

The GLP-1 War as a Case Study<\/strong><\/h3>\n\n\n\n

The GLP-1 category \u2014 semaglutide (Ozempic, Wegovy) from Novo Nordisk and tirzepatide (Mounjaro, Zepbound) from Eli Lilly \u2014 is the most visible DTC battleground. Both drugs faced a specific structural problem that accelerated their DTC moves: insurance coverage for weight loss indications was historically limited, which meant a large and growing patient population was already paying cash. That population was also shopping on telehealth platforms and, when shortages created FDA authorization for compounding, getting compounded versions at dramatically lower prices from compounding pharmacies.<\/p>\n\n\n\n

The launch of NovoCare Pharmacy followed the removal of semaglutide from the FDA’s shortage list and came a few months after rival Eli Lilly adopted a similar DTC strategy with LillyDirect for Zepbound. Both Novo Nordisk and Lilly are responding to competition from compounding pharmacies, which have been able to offer discounted versions of semaglutide and tirzepatide under FDA regulations applying to medicines deemed to be in short supply.<\/p>\n\n\n\n

Novo Nordisk partnered with telehealth company Hims & Hers \u2014 which previously sold compounded GLP-1s \u2014 with a bundled deal including all doses of Wegovy and a Hims & Hers membership for $599 per month. This move converted a competitor (Hims & Hers sold compounded semaglutide while it was on the shortage list) into a distribution partner once FDA shortage status ended. It is a channel management play dressed as a pricing play.<\/p>\n\n\n\n

LillyDirect offers Zepbound at discounted self-pay prices of $349 to $499 depending on dose. Patients receive vials \u2014 not pens \u2014 requiring self-measurement and injection. NovoCare provides Wegovy in pre-filled pens for easier administration at a flat $499 per month. The autoinjector availability is a competitive differentiator that gave NovoCare an early edge over LillyDirect’s vial-only offering.<\/p>\n\n\n\n

Under TrumpRx deals, both prices dropped further. Under MFN agreements, the prices of Ozempic and Wegovy fell from $1,000 and $1,350 per month, respectively, to $350 when purchased through TrumpRx. The price of Zepbound fell from $1,086 per month to an average of $346 through TrumpRx.<\/p>\n\n\n\n

None of this price action affects Cost Plus Drugs directly, since it operates in the generic market. But the GLP-1 DTC war demonstrates that the Cuban model \u2014 transparent pricing, bypass the middleman \u2014 has become the dominant template even for the brand manufacturers who most benefited from the opacity of the PBM system.<\/p>\n\n\n\n

The TrumpRx Factor<\/strong><\/h3>\n\n\n\n

The political dimension of this story arrived with force in 2025. Trump’s May 2025 Executive Order on Most-Favored Nation pricing, and the subsequent launch of TrumpRx.gov in February 2026, transformed what had been a market-driven transparency push into a direct government intervention.<\/p>\n\n\n\n

On May 12, 2025, President Trump signed an executive order titled ‘Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,’ directing the administration to take numerous actions to bring American drug prices in line with those paid by similar nations.<\/p>\n\n\n\n

Nine manufacturers \u2014 Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi \u2014 agreed to reduce prices on drugs that treat type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, COPD, hepatitis B and C, HIV, and certain cancers, providing every State Medicaid program access to MFN drug prices.<\/p>\n\n\n\n

By April 2026, President Trump had announced 17 MFN deals covering the 17 leading pharmaceutical manufacturers, representing 86% of the branded drug market. Each agreed to fundamentally rebalance international drug pricing by providing MFN pricing to American patients.<\/p>\n\n\n\n

Cost Plus Drugs formalized its alignment with TrumpRx at the HLTH conference in October 2025. At the HLTH conference’s keynote in Las Vegas, Cuban confirmed that Cost Plus Drugs would be collaborating with TrumpRx, President Trump’s direct purchasing platform. This was politically astute: Cuban has criticized PBMs regardless of which party is in power, and aligning with a government initiative that advances the same structural goal \u2014 cutting out middlemen \u2014 regardless of political branding is consistent with the Cost Plus mission.<\/p>\n\n\n\n

Industry analysts were cautious about the immediate market impact. Jesse Mendelsohn of Model N told Pharmaceutical Executive: “Right now, this is just another venue or route for patients to get therapy as opposed to a sea-change. Most people will typically use insurance for drugs. Since that’s the case, the things that impact how insurers reimburse for drugs and how manufacturers incentivize payers to list drugs aren’t going to change very much.”<\/p>\n\n\n\n

That caution is probably right in the short term. Most Americans do not pay cash for branded drugs. The TrumpRx prices on Ozempic and Wegovy are deeply discounted relative to list price but still out of reach for many patients without insurance. The 50 co-pay TrumpRx established for Medicare beneficiaries is more meaningful \u2014 it extends coverage to a population that previously had no access to GLP-1s through Medicare.<\/p>\n\n\n\n

Patent Strategy Adjustments: Evergreening Under Pressure<\/strong><\/h3>\n\n\n\n

Behind the consumer-facing DTC moves, manufacturers are also adjusting their patent strategies in response to the transparency pressure that Cost Plus created. The core question for any blockbuster drug approaching loss of exclusivity is whether the brand can maintain a meaningful revenue stream in a world where patients and employers know what the generic acquisition cost actually is.<\/p>\n\n\n\n

The traditional answers \u2014 secondary patent filings covering new formulations, once-daily dosing regimens, extended-release versions, and new combination products \u2014 are well-documented. What is changing is the speed at which these strategies are being deployed and the sophistication of the regulatory and legal infrastructure supporting them.<\/p>\n\n\n\n

The battleground in 2025 and 2026 is defined by two emerging trends: the assault on ‘skinny labeling’ and the fortification of patent thickets. Skinny labeling, enabled by Section viii of the Hatch-Waxman Act, allows a generic manufacturer to seek approval for a drug for unpatented indications while carving out patented uses from the label. Brand manufacturers have been increasingly aggressive in challenging skinny-label generics with induced infringement claims \u2014 arguing that even if the generic’s label does not include the patented indication, the generic manufacturer knows that physicians will prescribe it for that use.<\/p>\n\n\n\n

For Cost Plus Drugs, the skinny label battle matters because it affects which generics are commercially available and at what prices. If a generic manufacturer faces an induced infringement lawsuit that delays market entry, Cost Plus cannot add that drug to its formulary. The legal battles happening in federal district courts over skinny label generics are directly relevant to Cost Plus Drugs’ expansion roadmap.<\/p>\n\n\n\n

The average capitalized cost to bring a single new drug to market can exceed $2.6 billion, with recent figures placing the average at $2.23 billion in 2024. Consequently, the effective patent life \u2014 the actual period during which a drug is sold on the market with patent protection and without generic competition \u2014 typically averages only 7 to 12 years. That compression creates enormous pressure to extract maximum value during the exclusivity window. It also drives the patent thicket and secondary patent strategies that create the apparent gap between the nominal patent term and actual generic entry.<\/p>\n\n\n\n

Formulary Defensive Strategies<\/strong><\/h3>\n\n\n\n

The PBM defensive response to Cost Plus Drugs has been more structural than visible. Because PBMs control formulary access for the majority of insured Americans, they retain significant power to marginalize transparent-pricing alternatives, even as those alternatives become more prominent.<\/p>\n\n\n\n

The mechanism is straightforward: a PBM can design a formulary that requires patients to use preferred pharmacies \u2014 meaning PBM-affiliated specialty or retail pharmacies \u2014 for covered drugs. A patient whose employer’s plan requires specialty drugs to be dispensed through CVS Specialty cannot simply take their prescription to Cost Plus Drugs and get reimbursed. They pay full price out of pocket. The PBM’s preferred pharmacy network effectively walls off a large segment of the generic drug market from transparent-pricing competitors.<\/p>\n\n\n\n

Cuban has described this as the ‘specialty’ classification problem: ‘The PBMs have decided to take the drugs they can charge the most for and call them special. But there’s nothing special about most of these drugs. Many of these products are small molecule generic drugs. There’s nothing unique about the captive pharmacies they call special and force their customers to buy from.’<\/p>\n\n\n\n

The FTC has documented this concern explicitly. The July 2024 interim report found that PBM and brand drug manufacturer rebate contracts are expressly conditioned on limiting access to potentially lower-cost generic and biosimilar competitors [1]. That means the rebate structure actively incentivizes PBMs to block cheaper alternatives.<\/p>\n\n\n\n

The FTC did take enforcement action. On February 4, 2026, the Federal Trade Commission secured a settlement with Express Scripts, Inc. and its affiliated entities, requiring fundamental changes to business practices that are expected to drive down patients’ out-of-pocket costs for drugs like insulin by up to $7 billion over 10 years and bring millions of dollars in new revenue to community pharmacies each year.<\/p>\n\n\n\n

That settlement is meaningful, but it applies to a narrow set of drugs. The broader formulary gatekeeping practices that disadvantage Cost Plus Drugs and independent pharmacies remain largely intact across the system.<\/p>\n\n\n\n

\n\n\n\n

Part V: The Competitive Intelligence Framework You Need<\/strong><\/h2>\n\n\n\n

Modeling Cost Plus as a Threat vs. an Opportunity<\/strong><\/h3>\n\n\n\n

How you should be thinking about Cost Plus Drugs depends entirely on where you sit in the pharmaceutical supply chain.<\/p>\n\n\n\n

If you are a generic drug manufacturer, Cost Plus is a distribution channel that bypasses PBM markup and reaches patients directly. It is an opportunity, provided your production costs are low enough to permit the 15% markup model and still generate acceptable returns. Cost Plus Drugs’ platform gives generic manufacturers direct access to a price-sensitive consumer segment that PBMs would otherwise capture through preferred pharmacy steering.<\/p>\n\n\n\n

If you are a brand manufacturer with drugs approaching loss of exclusivity, Cost Plus is an accelerant of the revenue decline. When Cost Plus adds the generic version of your blockbuster to its formulary and sets it at $35 per month against your branded $500, the conversation with every employer health plan and hospital system in the country gets easier for the payer \u2014 and harder for you. The price transparency that Cost Plus creates is permanent. Even if a patient can’t use Cost Plus directly because of their insurance, the employer’s benefits consultant knows what the drug actually costs.<\/p>\n\n\n\n

If you are a PBM, Cost Plus Drugs is an existential threat in the medium term if the employer market embraces direct-to-employer models at scale. The SwiftyRx\/CenterWell partnership is explicitly designed to give self-insured employers a generic drug pricing channel that routes around Big 3 PBMs. If that model scales to even 5% of the employer market, the financial impact on PBM specialty drug dispensing revenue is material.<\/p>\n\n\n\n

If you are a hospital system, Cost Plus is a procurement opportunity for critical injectables in shortage, and a benchmark for what your current GPO (Group Purchasing Organization) contract prices should look like compared to true acquisition cost.<\/p>\n\n\n\n

If you are an investor or analyst, Cost Plus Drugs signals that the generic drug distribution margin is permanently under scrutiny. Any investment thesis that depends on PBM specialty drug spread pricing being sustainable over a five-to-ten year horizon should be stress-tested against the accelerating adoption of transparent-pricing alternatives.<\/p>\n\n\n\n

The Patent Cliff as Cost Plus Drugs’ Expansion Engine<\/strong><\/h3>\n\n\n\n

The $200-$300 billion patent cliff unfolding between 2025 and 2030 is not just a threat to brand manufacturers. It is the pipeline for Cost Plus Drugs’ formulary growth.<\/p>\n\n\n\n

Among the drugs facing loss of exclusivity: Merck’s Keytruda, a cancer immunotherapy with over $29 billion in 2024 sales, facing loss of exclusivity in 2028; Bristol Myers Squibb’s Eliquis, generating over $13 billion in 2024 revenue, with key patents expiring 2026-2028; Johnson and Johnson’s Darzalex, a $12 billion multiple myeloma franchise with patents expiring by 2029; and Novartis’s Entresto, a $7.8 billion heart failure drug facing generic competition as early as mid-2025.<\/p>\n\n\n\n

Each of those drugs \u2014 once generics enter and price competition drives acquisition cost down \u2014 is a candidate for Cost Plus Drugs’ formulary. The timing depends on patent litigation outcomes, which DrugPatentWatch tracks in real time through its patent expiration databases and ANDA filing data. For competitive intelligence professionals monitoring Cost Plus Drugs’ strategic trajectory, those patent timelines are the most important forward-looking indicator.<\/p>\n\n\n\n

Entresto is particularly instructive. Sacubitril\/valsartan is a combination product for heart failure treatment with a large and growing patient population. Its $7.8 billion revenue base means that once generics enter, the price compression will be dramatic. A patient currently paying $400-500 per month for brand Entresto could pay $30-50 per month for generic sacubitril\/valsartan through a Cost Plus-style pricing model. That savings magnitude \u2014 repeated across millions of heart failure patients \u2014 reshapes the employer health plan calculus on formulary design in ways that PBMs cannot simply offset with rebate adjustments.<\/p>\n\n\n\n

The Role of Patent Intelligence Platforms<\/strong><\/h3>\n\n\n\n

For any organization tracking Cost Plus Drugs’ strategic moves against Big Pharma’s defensive responses, patent intelligence is the foundation. Understanding which drugs are approaching loss of exclusivity, which ANDA filings have been made, which Paragraph IV certifications are pending litigation, and which settlement agreements are volume-capping generic entry \u2014 this is the data layer beneath the commercial dynamics.<\/p>\n\n\n\n

DrugPatentWatch has built the most comprehensive database of U.S. pharmaceutical patent expiration data and ANDA filing history in the market. For procurement professionals trying to time generic formulary additions, for generic manufacturers assessing first-to-file opportunities, for investors modeling the revenue cliff exposure of brand companies, and for cost intelligence professionals trying to understand what a drug should cost versus what it actually costs, this kind of platform provides the structural intelligence that public information sources cannot.<\/p>\n\n\n\n

The specific use cases are worth spelling out:<\/p>\n\n\n\n

A self-insured employer benefit consultant can use patent expiration data to identify which of their high-cost brand drugs will have generic alternatives within 12-24 months, and plan formulary transitions accordingly. This kind of anticipatory formulary management \u2014 moving employees to generic equivalents the moment they become available \u2014 can save millions per year for a large employer and is exactly the kind of leverage that Cost Plus Drugs’ transparency model makes possible.<\/p>\n\n\n\n

A generic drug manufacturer can use ANDA filing data to assess the competitive landscape for a specific molecule before committing to development investment. If 15 generic manufacturers have already filed ANDAs on a molecule, the 180-day first-to-file exclusivity opportunity is gone, and the post-exclusivity price will compress rapidly. If only two have filed, the competitive dynamics are very different.<\/p>\n\n\n\n

An investor in pharmaceutical companies can use patent cliff analysis to model the revenue trajectory of a company’s key assets with greater precision than sell-side estimates typically provide. The gap between the nominal patent expiration date and actual generic entry \u2014 which can span anywhere from zero to six-plus years depending on litigation outcomes \u2014 is where most of the analytical uncertainty lives.<\/p>\n\n\n\n

The Regulatory Environment as Strategic Variable<\/strong><\/h3>\n\n\n\n

Cost Plus Drugs operates in a regulatory environment that has shifted materially since its launch. The IRA, the MFN executive orders, the FTC’s two interim reports on PBMs, and the ESI settlement have all moved in the direction of greater pricing transparency and reduced PBM pricing power. Whether this regulatory trajectory continues or reverses is the key uncertainty in any five-year strategic model.<\/p>\n\n\n\n

The IRA introduced a new mechanism for drug price negotiation that operates independently of the patent system. The Inflation Reduction Act represents the most significant change to U.S. pharmaceutical pricing policy in decades. Its drug price negotiation provisions, which apply to high-expenditure drugs covered by Medicare, have created a new type of LOE event that operates independently of patent expiration. A drug subject to IRA negotiation sees a Congressionally mandated price reduction even while its patents remain in force. That is a fundamentally different structure than the generic entry model, and it changes the revenue trajectory of affected drugs in ways that patent expiration models alone cannot capture.<\/p>\n\n\n\n

With the IRA, MFN pricing, and 340B changing the drug pricing calculus, and patients seeking convenience, DTC could become essential for success in today’s pharmaceutical market. Manufacturers exploring these strategies must work through the complexity of the patient journey, understand the impact of formulary access, balance net prices, and work through the logistics of program design.<\/p>\n\n\n\n

The 340B program adds another layer. Hospital systems and qualified health centers that participate in 340B can purchase drugs at mandatory discount prices \u2014 often below even Cost Plus acquisition costs for some drugs \u2014 creating a procurement advantage that narrows the Cost Plus value proposition in the institutional channel.<\/p>\n\n\n\n

What this regulatory complexity means for strategic planning is that the pharmaceutical supply chain is being pressured from multiple directions simultaneously: from below by Cost Plus-style transparency and generic competition, from above by government price negotiation and MFN requirements, and laterally by the FTC’s enforcement actions against PBM anticompetitive practices. No single factor explains the full picture. The strategic response needs to account for all of them.<\/p>\n\n\n\n

\n\n\n\n

Part VI: The Forward Models<\/strong><\/h2>\n\n\n\n

Scenario 1: Cost Plus Scales Through Employer Direct<\/strong><\/h3>\n\n\n\n

The most bullish scenario for Cost Plus Drugs involves the employer direct model gaining rapid adoption among large self-insured employers. If the SwiftyRx\/CenterWell partnership delivers demonstrable savings on generic drug costs for a cohort of large employers, and those savings are auditable and repeatable, the referral dynamics in the HR benefits community are powerful. Benefits consultants who identify a $500-per-employee-per-year savings opportunity from switching generic drug procurement to a Cost Plus-affiliated model have strong financial incentives to recommend that switch to their clients.<\/p>\n\n\n\n

The math works at scale in a way it does not work in the individual consumer market. An employer with 10,000 employees and an average generic drug cost of $400 per year per employee is spending $4 million on generic drugs. If Cost Plus pricing reduces that acquisition cost by 30% \u2014 a conservative estimate for drugs currently dispensed through PBM-affiliated specialty pharmacies \u2014 the savings are $1.2 million per year. Over a 5,000-employer cohort, that is $6 billion per year in aggregate savings. PBMs cannot afford for this model to succeed at that scale.<\/p>\n\n\n\n

In this scenario, the competitive response from PBMs is formulary retaliation: threatening to remove employer clients from preferred pricing tiers if they route generic drugs around the PBM network. Some employers will capitulate. Others \u2014 particularly those in industries where health benefits are a competitive differentiator for talent recruitment \u2014 will not. The market segments.<\/p>\n\n\n\n

Scenario 2: The Regulatory Backlash Limits Scale<\/strong><\/h3>\n\n\n\n

The more cautious scenario involves regulatory friction limiting Cost Plus Drugs’ employer market expansion. PBMs have significant lobbying resources and existing relationships with state insurance regulators. If PBM trade associations are able to shape regulatory requirements around pharmacy benefit programs in ways that require employer plans to use licensed and accredited pharmacy networks \u2014 and if Cost Plus Drugs or its SwiftyRx-integrated pharmacy partners do not meet those accreditation standards \u2014 growth is constrained.<\/p>\n\n\n\n

There is also the question of whether the FTC’s enforcement posture toward PBMs sustains under the current administration. The Biden-era FTC was aggressive on PBM anticompetitive practices. The Trump-era FTC has different priorities. The Express Scripts settlement in February 2026 suggests that enforcement is continuing, but the pace and scope of future actions are uncertain.<\/p>\n\n\n\n

In this scenario, Cost Plus Drugs remains a meaningful niche player in the consumer generic market and a selective partner for hospital systems on critical injectables, but does not achieve the scale necessary to materially reshape the employer drug benefit market.<\/p>\n\n\n\n

Scenario 3: The Manufacturing Wedge<\/strong><\/h3>\n\n\n\n

The most underappreciated path to scale for Cost Plus Drugs runs through manufacturing rather than pharmacy. If the Dallas facility can demonstrate consistent quality, agile production of shortage drugs, and the ability to add pediatric oncology and other critical drugs that no one else is making economically, the company’s value proposition shifts from “cheaper generics” to “supply chain resilience.”<\/p>\n\n\n\n

Hospital systems pay enormous premiums during drug shortage periods. When epinephrine is scarce, a hospital will pay whatever it takes. If Cost Plus can supply high-shortage injectable drugs at transparent cost-plus prices during shortage events while competitors are either out of stock or demanding crisis pricing, the institutional customer relationship deepens in ways that the consumer model cannot replicate.<\/p>\n\n\n\n

This manufacturing path also aligns most naturally with federal policy objectives. The Trump administration’s push for domestic pharmaceutical manufacturing \u2014 including the 100% tariff threat on imported branded drugs unless manufacturers build U.S. plants \u2014 creates a political tailwind for a company that is already manufacturing domestically. Cuban’s meetings at the White House are not incidental; they reflect a genuine alignment of interest between a policy agenda seeking domestic drug security and a company that is actually building the manufacturing capacity that agenda requires.<\/p>\n\n\n\n

What Big Pharma Should Have Been Doing \u2014 and Wasn’t<\/strong><\/h3>\n\n\n\n

The counterfactual worth examining: what would the pharmaceutical industry look like today if brand manufacturers had responded to the transparency pressure in 2015 \u2014 when Martin Shkreli’s Daraprim pricing made drug costs a national conversation \u2014 rather than waiting until Cuban forced the issue in 2022?<\/p>\n\n\n\n

The answer, probably, is that the DTC models being launched today would have been launched then. Manufacturers would have competed on the access layer, built direct relationships with patients, and reduced the PBM’s information advantage. The rebate system would have faced pressure earlier. The FTC would have had more market evidence of competitive alternatives when it began its PBM investigation.<\/p>\n\n\n\n

Instead, the industry doubled down on list price increases, patent thickets, and PBM rebate maximization. That strategy delivered strong near-term financial results and set up a political backlash that now includes bipartisan FTC investigations, executive orders on MFN pricing, Senate Finance Committee hearings, and a DTC platform backed by the federal government itself.<\/p>\n\n\n\n

The lesson for strategic planning is direct: pricing opacity that requires external pressure to break does eventually break. When it breaks, it breaks all at once. The companies that prepared for the transparency transition \u2014 that modeled what their products would cost in a Cost Plus-style market and built their R&D and commercial pipelines accordingly \u2014 are better positioned than those that treated opacity as a permanent competitive advantage.<\/p>\n\n\n\n

\n\n\n\n

Part VII: What Practitioners Need to Model Right Now<\/strong><\/h2>\n\n\n\n

The Generic Drug Procurement Decision<\/strong><\/h3>\n\n\n\n

For self-insured employers, the practical decision framework is whether to maintain your existing PBM relationship for generic drug procurement, move to a carve-out arrangement that routes generics through a transparent-pricing channel like Cost Plus Drugs, or negotiate with your existing PBM to match Cost Plus pricing as a condition of contract renewal.<\/p>\n\n\n\n

The third option \u2014 negotiating with your PBM using Cost Plus pricing as a benchmark \u2014 is the lowest-friction path and the one most large employers are currently exploring. The information that Cost Plus publishes on its website, and the comparable data available through platforms like GoodRx and DrugPatentWatch’s price intelligence features, gives employer benefits teams a factual basis for that negotiation that did not exist before January 2022.<\/p>\n\n\n\n

The key variables in this analysis: what percentage of your total pharmacy spend is on generic drugs (typically 85-90% of prescription volume but only 20-30% of total drug spend), what percentage of those generics are classified as “specialty” by your current PBM (and thus dispensed through PBM-affiliated specialty pharmacies at inflated margins), and what is the spread between your current contracted price and Cost Plus acquisition cost for those drugs.<\/p>\n\n\n\n

For most large employers, the answer to the last question will reveal that 20-40% of generic drug spend is absorbing PBM markup that serves no clinical function. That is the savings opportunity Cost Plus Drugs makes legible.<\/p>\n\n\n\n

The Patent Expiration Calendar<\/strong><\/h3>\n\n\n\n

For pharmaceutical executives managing product portfolios, the patent expiration calendar for the next five years should be the foundation of every commercial strategy review. The drugs at risk between now and 2030 represent the largest single wave of generic competition in pharmaceutical history.<\/p>\n\n\n\n

Analyst reports suggest that five of the top ten pharmaceutical firms face revenue exposure exceeding 50% of their current revenue from the current patent cliff. For companies like Bristol Myers Squibb, Pfizer, and Novartis, the revenue generated by just their top five drugs is projected to decrease by as much as 62% by 2030.<\/p>\n\n\n\n

Against that backdrop, the DTC pricing moves made by BMS on Eliquis, Novo Nordisk on Wegovy, and AstraZeneca across its portfolio are best understood as brand defense under generic threat rather than cost-reduction altruism. A manufacturer that launches a direct-to-consumer program offering Eliquis at 80% off list price before generics enter the market is buying patient loyalty and brand relationships that it hopes will persist into the post-generic period. Whether patients and health plans prefer branded apixaban at $100 per month over generic apixaban at $15 per month is an open question. Historical data suggests they will not, but the manufacturers are betting that the direct relationship changes the calculus.<\/p>\n\n\n\n

The Regulatory Monitoring Imperative<\/strong><\/h3>\n\n\n\n

No strategic model of the pharmaceutical pricing landscape holds still for very long. The regulatory variables \u2014 IRA drug price negotiations, MFN executive orders, FTC enforcement actions, congressional PBM legislation, state-level PBM reform bills \u2014 are changing the structural economics of the business in real time.<\/p>\n\n\n\n

Analysts and executives who built pharmaceutical pricing models in 2020 and have not fundamentally revised them since the IRA passed in 2022 are working with a framework that no longer maps to reality. The IRA created a de facto cap on the revenue trajectory of any drug subject to Medicare price negotiation. The MFN executive order created a new negotiating floor that brands must defend. The FTC’s enforcement activity on PBM specialty drug pricing created new legal risk for spread pricing practices that have been industry standard for years.<\/p>\n\n\n\n

For competitive intelligence teams, the practical implication is that monitoring needs to cover four streams simultaneously: patent expiration and ANDA filing data (which determines when generic competition arrives), regulatory policy changes (which alter pricing dynamics for drugs in the pre-generic period), FTC and DOJ enforcement activity (which constrains PBM behavior and creates channel opportunities for alternatives like Cost Plus), and manufacturer DTC announcements (which signal where brand companies believe the competitive threat is sharpest).<\/p>\n\n\n\n

For the Investor<\/strong><\/h3>\n\n\n\n

If you are modeling pharmaceutical company valuations, the Cost Plus Drugs effect on generic drug pricing intelligence deserves explicit treatment. Before January 2022, the true acquisition cost of most generic drugs was opaque. PBMs, wholesalers, and retailers all extracted margin from a price waterfall that no external party could accurately reconstruct. That opacity supported premium valuations for companies whose business models depended on it.<\/p>\n\n\n\n

Cost Plus Drugs published the acquisition cost. GoodRx and Amazon Pharmacy have since competed to show similar pricing. The opacity is gone for the generic market, and it is progressively eroding in the brand market through the DTC pricing transparency that MFN agreements are forcing. Valuation models that incorporate PBM specialty drug margin as a durable competitive moat are increasingly wrong.<\/p>\n\n\n\n

The companies that are correctly positioned in this environment are those with robust pipeline depth, manufacturing efficiency advantages, and therapeutic areas where generic competition dynamics are unfavorable to Cost Plus-style pricing \u2014 primarily biologics, where the regulatory and manufacturing complexity of biosimilar development creates slower and less complete price erosion than small-molecule generics experience.<\/p>\n\n\n\n

\n\n\n\n

Key Takeaways<\/strong><\/h2>\n\n\n\n

Cost Plus Drugs changed the information environment.<\/strong> Before January 2022, the true acquisition cost of generic drugs was effectively hidden from employers, patients, and health plans. Publishing that cost shifted negotiating leverage across the supply chain permanently. The information cannot be un-published.<\/p>\n\n\n\n

The employer channel is the real market.<\/strong> The consumer DTC model is limited to cash-paying patients outside the insurance system \u2014 a real but niche population. The SwiftyRx\/CenterWell employer model, if it scales, routes generic drug procurement for insured Americans around PBM markup. That is an order-of-magnitude larger opportunity.<\/p>\n\n\n\n

Manufacturing is underappreciated.<\/strong> The Dallas facility’s focus on critical injectable drug shortages positions Cost Plus Drugs as a supply chain resilience play, not just a pricing play. Hospital systems and federal policy both need domestic manufacturers of shortage-prone drugs. Cuban’s company is building that capacity.<\/p>\n\n\n\n

Big Pharma’s DTC response preserves, rather than dismantles, the rebate system.<\/strong> Manufacturer-owned DTC platforms offer patient-facing discounts while keeping list prices (and thus PBM rebate calculations) intact. They are a tactical response to the transparency pressure Cost Plus created, not a structural dismantling of the PBM model. The difference matters for how much savings actually flows to patients versus how much is captured in the brand defense.<\/p>\n\n\n\n

The patent cliff is Cost Plus Drugs’ growth engine.<\/strong> Every blockbuster drug that loses exclusivity between 2025 and 2030 is a potential formulary addition. Tracking patent expiration timelines, ANDA filing data, and Paragraph IV litigation outcomes is essential for modeling Cost Plus’s formulary expansion and the corresponding pressure on brand manufacturers.<\/p>\n\n\n\n

PBM dominance is structurally fragile.<\/strong> The FTC’s documentation that six PBMs manage 94% of U.S. prescriptions, combined with the ESI settlement, the congressional attention, and the competitive alternatives Cost Plus has made credible, marks a genuine erosion of the conditions that made that concentration durable. The legal and regulatory pressure will not resolve this year or next year. Over five to ten years, it is hard to see how that level of market concentration survives intact.<\/p>\n\n\n\n

Regulatory variables are now first-order strategic inputs.<\/strong> The IRA, MFN pricing, and FTC enforcement have each materially altered the economics of pharmaceutical pricing in ways that make 2019-vintage competitive models unreliable. Organizations that are not explicitly incorporating regulatory scenarios into their pharmaceutical pricing strategy are operating with an incomplete picture.<\/p>\n\n\n\n

\n\n\n\n

FAQ<\/strong><\/h2>\n\n\n\n

Q1: Does Cost Plus Drugs actually threaten large PBMs’ core business, or is it too small to matter?<\/strong><\/p>\n\n\n\n

In the consumer market, it is currently too small to matter to PBM revenue directly. Cost Plus Drugs has roughly 2 million members and carries approximately 2,500 generic drugs. The Big 3 PBMs manage 6.6 billion prescriptions annually across 270 million Americans. The volume disparity is not close.<\/p>\n\n\n\n

Where Cost Plus matters is in information and negotiating dynamics, not in market share. Every large employer’s benefits team now knows what generic drug acquisition costs look like. That knowledge changes contract negotiations with PBMs regardless of whether the employer actually switches to Cost Plus. The second-order effect \u2014 PBMs under more intense price scrutiny from employers armed with Cost Plus benchmarks \u2014 is already visible in the industry’s conversation about pricing transparency. The employer direct model, if it achieves meaningful scale through SwiftyRx and CenterWell, shifts the analysis from information threat to volume threat.<\/p>\n\n\n\n

Q2: Why haven’t pharmaceutical manufacturers cut off Cost Plus Drugs by refusing to sell them generic APIs at low prices?<\/strong><\/p>\n\n\n\n

Cost Plus Drugs purchases generics from generic manufacturers \u2014 companies like Teva, Sandoz, Mylan (now Viatris), and others \u2014 not from brand manufacturers. Generic manufacturers have no commercial incentive to refuse sales to Cost Plus; they sell API and finished product at acquisition cost and Cost Plus provides a direct-to-consumer channel that bypasses the PBM markup the generic manufacturer never captured anyway. The relationship is straightforwardly commercial. Where Cuban has reported friction is with brand manufacturers and PBMs blocking direct-to-consumer access to brand drugs and to the specialty distribution channels that PBMs control.<\/p>\n\n\n\n

Q3: How does the TrumpRx partnership affect Cost Plus Drugs’ independence and long-term positioning?<\/strong><\/p>\n\n\n\n

The TrumpRx alignment is politically practical for Cost Plus Drugs but carries reputational risk. If TrumpRx fails to achieve broad adoption, or if the administration’s drug pricing agenda reverses course \u2014 as presidential executive orders on drug pricing have historically done in litigation \u2014 the Cost Plus association with TrumpRx becomes a liability rather than an asset. Cuban has been careful to frame the TrumpRx collaboration as aligned with Cost Plus’s mission regardless of political branding: if the platform gets patients cheaper drugs by cutting out middlemen, the mechanics are the same whether the platform is called TrumpRx or something else. That framing is durable. The specific government partnership is not guaranteed to be.<\/p>\n\n\n\n

Q4: Which drugs on the 2025-2030 patent cliff represent the largest formulary opportunity for Cost Plus Drugs?<\/strong><\/p>\n\n\n\n

Small-molecule drugs with large patient populations and simple manufacturing profiles represent the clearest opportunities. Eliquis (apixaban), once generic competition fully arrives following the 2026-2028 patent resolution window, will treat tens of millions of atrial fibrillation and DVT patients. Its current brand price of $13 billion in annual revenue will compress dramatically. Entresto (sacubitril\/valsartan) faces a large heart failure patient population. Drugs in psychiatry, neurology, and cardiology \u2014 which the PharmacoEconomics study found produced the highest absolute savings when Cost Plus pricing was applied \u2014 are the categories with the largest impact.<\/p>\n\n\n\n

Biologic and biosimilar opportunities are different in character. The slower erosion curve for biologics (20-30% biosimilar market share after two years, versus 80-90% for small molecules) means that even after formal loss of exclusivity, the price compression that Cost Plus needs to add a drug to its formulary at a meaningful patient savings may not materialize for three to four years post-LOE.<\/p>\n\n\n\n

Q5: What should a pharmaceutical manufacturer do right now if its leading product faces loss of exclusivity within three years?<\/strong><\/p>\n\n\n\n

Three specific moves are worth modeling. First, build a direct patient relationship before generic entry. The manufacturers who had DTC infrastructure in place when generics arrived had data on patient preferences, adherence patterns, and brand loyalty that informed their post-generic commercial strategy. Building that infrastructure after generic entry is more expensive and less effective. Second, use the brand period to demonstrate clinical differentiation \u2014 extended-release formulations, specific dosing regimens, device combinations \u2014 that creates genuine reasons for prescribers to prefer the brand over the generic even at a price premium, not just patented reasons. The distinction matters: truly differentiated clinical profiles sustain premium pricing; patent barriers eventually fall. Third, model the post-generic world honestly. The companies that were surprised by how fast Humira’s revenue fell were not doing their scenario planning correctly. The 80-90% revenue compression for small-molecule generic entry within the first year is well-documented. If your lead product goes generic in 2027, you need a replacement revenue stream generating material revenue by 2026. If you don’t have one, the pipeline decisions you need to make are already late.<\/p>\n\n\n\n

\n\n\n\n

Citations<\/strong><\/h2>\n\n\n\n

[1] Federal Trade Commission. (2024, July 9). Pharmacy benefit managers: The powerful middlemen inflating drug costs and squeezing main street pharmacies<\/em> [Interim Staff Report]. FTC. https:\/\/www.ftc.gov\/reports\/pharmacy-benefit-managers-report<\/p>\n\n\n\n

[2] Federal Trade Commission. (2025, January 14). FTC releases second interim staff report on prescription drug middlemen<\/em> [Press Release]. FTC. https:\/\/www.ftc.gov\/news-events\/news\/press-releases\/2025\/01\/ftc-releases-second-interim-staff-report-prescription-drug-middlemen<\/p>\n\n\n\n

[3] Schmalfuhs, M. (2024, June 7). Pharm Exec exclusive: Mark Cuban talks drug pricing. Pharmaceutical Executive<\/em>, 44(6). https:\/\/www.pharmexec.com\/view\/pharm-exec-exclusive-mark-cuban-talks-drug-pricing<\/p>\n\n\n\n

[4] Emanuel, E. J., & Connolly, J. (2024, July 29). Mark Cuban Cost Plus Drugs: More impact on shortages than costs. STAT News<\/em>. https:\/\/www.statnews.com\/2024\/07\/29\/mark-cuban-cost-plus-drug-company-bigger-impact-drug-shortages-not-drug-costs\/<\/p>\n\n\n\n

[5] Cuban, M. (2024, March). Mark Cuban: Five ways that big PBMs hurt U.S. healthcare \u2014 and how we can fix it. Drug Channels<\/em>. https:\/\/www.drugchannels.net\/2024\/03\/mark-cuban-five-ways-that-big-pbms-hurt.html<\/p>\n\n\n\n

[6] Landi, H. (2024, March 4). Mark Cuban says Cost Plus Drugs targeting generic meds in short supply as it opens manufacturing facility. Fierce Healthcare<\/em>. https:\/\/www.fiercehealthcare.com\/health-tech\/mark-cuban-says-cost-plus-drugs-has-couple-million-patients-2500-generic-drugs-it-moves<\/p>\n\n\n\n

[7] Penn LDI. (2025, January 8). Mark Cuban explains his battle against pharmacy benefit managers. Leonard Davis Institute of Health Economics<\/em>. https:\/\/ldi.upenn.edu\/our-work\/research-updates\/mark-cuban-explains-his-battle-against-pharmacy-benefit-managers\/<\/p>\n\n\n\n

[8] Becker’s Hospital Review. (2024, March 5). Mark Cuban’s pharma company to start manufacturing 2 drugs this week. Becker’s Hospital Review<\/em>. https:\/\/www.beckershospitalreview.com\/pharmacy\/mark-cubans-pharma-company-to-start-manufacturing-2-drugs-this-week\/<\/p>\n\n\n\n

[9] Japsen, B. (2025, December 4). Humana and Mark Cuban’s Cost Plus Drugs working on partnership to lower prices. Forbes<\/em>. https:\/\/www.forbes.com\/sites\/brucejapsen\/2025\/12\/04\/humana-mark-cubans-cost-plus-drugs-working-on-partnership\/<\/p>\n\n\n\n

[10] Fierce Healthcare. (2026, April 27). Humana’s CenterWell, Mark Cuban’s Cost Plus Drugs partner to tackle employers’ drug costs. Fierce Healthcare<\/em>. https:\/\/www.fiercehealthcare.com\/payers\/humanas-centerwell-mark-cubans-cost-plus-drugs-handle-employers-prescriptions<\/p>\n\n\n\n

[11] Vogel, S. (2025, October 20). Mark Cuban says Cost Plus Drugs will partner with TrumpRx. Healthcare Dive<\/em>. https:\/\/www.healthcaredive.com\/news\/mark-cuban-cost-plus-drugs-partner-trumprx\/803180\/<\/p>\n\n\n\n

[12] White House. (2025, May 12). Delivering most-favored-nation prescription drug pricing to American patients<\/em> [Executive Order]. https:\/\/www.whitehouse.gov\/presidential-actions\/2025\/05\/delivering-most-favored-nation-prescription-drug-pricing-to-american-patients\/<\/p>\n\n\n\n

[13] White House. (2026, February 5). Fact sheet: President Donald J. Trump launches TrumpRx.gov to bring lower drug prices to American patients<\/em>. https:\/\/www.whitehouse.gov\/fact-sheets\/2026\/02\/fact-sheet-president-donald-j-trump-launches-trumprx-gov-to-bring-lower-drug-prices-to-american-patients\/<\/p>\n\n\n\n

[14] White House. (2025, November 6). Fact sheet: President Donald J. Trump announces major developments in bringing most-favored-nation pricing to American patients<\/em>. https:\/\/www.whitehouse.gov\/fact-sheets\/2025\/11\/fact-sheet-president-donald-j-trump-announces-major-developments-in-bringing-most-favored-nation-pricing-to-american-patients\/<\/p>\n\n\n\n

[15] DrugPatentWatch. (2026, February 25). Beyond the drug patent cliff: How procurement can drive immediate savings with generics and biosimilars. https:\/\/www.drugpatentwatch.com\/blog\/beyond-the-drug-patent-cliff-how-procurement-can-drive-immediate-savings-with-generics-and-biosimilars\/<\/p>\n\n\n\n

[16] DrugPatentWatch. (2026, March 10). The patent cliff playbook: Pharmaceutical IP valuation, generic entry timing, and biosimilar strategy. https:\/\/www.drugpatentwatch.com\/blog\/patent-expirations-seizing-opportunities-in-the-generic-drug-market\/<\/p>\n\n\n\n

[17] DrugPatentWatch. (2025, November 19). Forging strategic partnerships to conquer the $400 billion patent cliff. https:\/\/www.drugpatentwatch.com\/blog\/forging-strategic-partnerships-to-conquer-the-400-billion-patent-cliff\/<\/p>\n\n\n\n

[18] DrugPatentWatch. (2026, January 22). The patent cliff and beyond: A definitive guide to generic and biosimilar market entry. https:\/\/www.drugpatentwatch.com\/blog\/generic-drug-entry-timeline-predicting-market-dynamics-after-patent-loss\/<\/p>\n\n\n\n

[19] Hollan, M. (2025). How will TrumpRx impact manufacturer-produced DTC programs? Pharmaceutical Executive<\/em>. https:\/\/www.pharmexec.com\/view\/trumprx-impact-manufacturer-produced-dtc-programs<\/p>\n\n\n\n

[20] Pharma Technology. (2025, August 19). Trade-offs abound as big pharma makes direct-to-consumer transition. Pharmaceutical Technology<\/em>. https:\/\/www.pharmaceutical-technology.com\/news\/trade-offs-abound-as-big-pharma-makes-direct-to-consumer-transition\/<\/p>\n\n\n\n

[21] IQVIA. (2025). Why pharma is going direct to consumers. https:\/\/www.iqvia.com\/locations\/united-states\/blogs\/2025\/08\/why-pharma-is-going-direct-to-consumers<\/p>\n\n\n\n

[22] Galen Growth. (2025, November 25). Pharma’s direct-to-patient pivot (2025): LillyDirect, PfizerForAll & NovoCare models. https:\/\/www.galengrowth.com\/pharmas-direct-to-patient-pivot-2025\/<\/p>\n\n\n\n

[23] PharmExec. (2025, December 19). Most-favored-nation policy: Outlook and implications beyond U.S. Pharmaceutical Executive<\/em>. https:\/\/www.pharmexec.com\/view\/most-favored-nation-policy-outlook-implications-beyond<\/p>\n\n\n\n

[24] Community Health Systems. (2024, March 7). Community Health Systems partners with Mark Cuban Cost Plus Drug Company. CHS Press Release<\/em>. https:\/\/chsnet.gcs-web.com\/news-releases\/news-release-details\/community-health-systems-partners-mark-cuban-cost-plus-drug<\/p>\n\n\n\n

[25] Cuban, M., quoted in Fortune. (2025, October 2). Mark Cuban says Trump’s new drug platform could succeed if it forces pharma managers to change. Fortune<\/em>. https:\/\/fortune.com\/2025\/10\/02\/mark-cuban-trump-drug-platform-impactful\/<\/p>\n\n\n\n

[26] Federal Trade Commission. (2024, July 9). FTC releases interim staff report on prescription drug middlemen<\/em> [Press Release]. FTC. https:\/\/www.ftc.gov\/news-events\/news\/press-releases\/2024\/07\/ftc-releases-interim-staff-report-prescription-drug-middlemen<\/p>\n\n\n\n

[27] Federal Trade Commission. (2026, February 4). FTC secures settlement with Express Scripts. FTC<\/em>. https:\/\/www.ftc.gov\/terms\/pharmacy-benefits-managers-pbm<\/p>\n\n\n\n

[28] Saraceno, N. (2025, December). Mark Cuban pushes for generic drug fee waivers, as Cost Plus Drugs eyes U.S. manufacturing expansion. Pharmaceutical Commerce<\/em>. https:\/\/www.pharmaceuticalcommerce.com\/view\/mark-cuban-pushes-for-generic-drug-fee-waivers<\/p>\n\n\n\n

[29] Pharmaphorum. (2025, March 6). Novo Nordisk follows Lilly into DTC obesity drug market. Pharmaphorum<\/em>. https:\/\/pharmaphorum.com\/news\/novo-nordisk-follows-lilly-dtc-obesity-drug-market<\/p>\n\n\n\n

[30] Georgetown Medicare Policy Initiative. (2025). Drug pricing in the era of Trump 2.0. https:\/\/medicare.chir.georgetown.edu\/drug-pricing-in-the-era-of-trump-2-0\/<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Mark Cuban did not build a pharmacy. He built a mirror and pointed it at an industry that had never […]<\/p>\n","protected":false},"author":1,"featured_media":38577,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-38572","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38572","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=38572"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38572\/revisions"}],"predecessor-version":[{"id":38578,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38572\/revisions\/38578"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/38577"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=38572"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=38572"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=38572"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}